elan corporation plc annual report 1997 page 1 contents financial highlights 3 chairman s statement 4 deciphering alzheimer disease 12 epilepsy an overview 16 parkinson 20 drug delivery 24 principal business locations 28 statements 29 directors officers and other information 73 shareholder services 75 10 year summary 76 2 is a research based biopharmaceutical company for over 25 years has been leader in the development application of technologies which are designed to increase therapeutic value decrease side effects medications improve patient outcomes lower health care cost through its athena neurosciences division expanded capabilities into discovery marketing agents diagnosis treatment central nervous system diseases disorders months 31 december 1996 us 000s operations gaap revenue 389 156 310 420 operating profit 133 606 103 018 retained 175 114 115 916 diluted earnings per ordinary share 58 26
